首页> 美国卫生研究院文献>Drug Design Development and Therapy >Smart nanocrystals of artemether: fabrication characterization and comparative in vitro and in vivo antimalarial evaluation
【2h】

Smart nanocrystals of artemether: fabrication characterization and comparative in vitro and in vivo antimalarial evaluation

机译:蒿甲醚的智能纳米晶体:制备表征以及体外和体内抗疟药评价的比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Artemether (ARTM) is a very effective antimalarial drug with poor solubility and consequently low bioavailability. Smart nanocrystals of ARTM with particle size of 161±1.5 nm and polydispersity index of 0.172±0.01 were produced in <1 hour using a wet milling technology, Dena® DM-100. The crystallinity of the processed ARTM was confirmed using differential scanning calorimetry and powder X-ray diffraction. The saturation solubility of the ARTM nanocrystals was substantially increased to 900 µg/mL compared to the raw ARTM in water (145.0±2.3 µg/mL) and stabilizer solution (300.0±2.0 µg/mL). The physical stability studies conducted for 90 days demonstrated that nanocrystals stored at 2°C–8°C and 25°C were very stable compared to the samples stored at 40°C. The nanocrystals were also shown to be stable when processed at acidic pH (2.0). The solubility and dissolution rate of ARTM nanocrystals were significantly increased (P<0.05) compared to those of its bulk powder form. The results of in vitro studies showed significant antimalarial effect (P<0.05) against Plasmodium falciparum and Plasmodium vivax. The IC50 (median lethal oral dose) value of ARTM nanocrystals was 28- and 54-fold lower than the IC50 value of unprocessed drug and 13- and 21-fold lower than the IC50 value of the marketed tablets, respectively. In addition, ARTM nanocrystals at the same dose (2 mg/kg) showed significantly (P<0.05) higher reduction in percent parasitemia (89%) against P. vivax compared to the unprocessed (27%), marketed tablets (45%), and microsuspension (60%). The acute toxicity study demonstrated that the LD50 value of ARTM nanocrystals is between 1,500 mg/kg and 2,000 mg/kg when given orally. This study demonstrated that the wet milling technology (Dena® DM-100) can produce smart nanocrystals of ARTM with enhanced antimalarial activities.
机译:蒿甲醚(ARTM)是一种非常有效的抗疟药,溶解性差,因此生物利用度低。使用湿磨技术Dena ® DM-100,在不到1小时的时间内即可生产出粒径为161±1.5 nm,多分散指数为0.172±0.01的ARTM智能纳米晶体。使用差示扫描量热法和粉末X射线衍射确认加工的ARTM的结晶度。与原始ARTM在水中(145.0±2.3 µg / mL)和稳定剂溶液(300.0±2.0 µg / mL)相比,ARTM纳米晶体的饱和溶解度显着提高至900 µg / mL。进行90天的物理稳定性研究表明,与40°C的样品相比,在2°C–8°C和25°C的温度下保存的纳米晶体非常稳定。当在酸性pH(2.0)下处理时,纳米晶体也显示出稳定的性能。与散装粉末相比,ARTM纳米晶体的溶解度和溶解速率显着提高(P <0.05)。体外研究结果显示对恶性疟原虫和间日疟原虫具有显着的抗疟作用(P <0.05)。 ARTM纳米晶体的IC50(中等致死口服剂量)值分别比未加工药物的IC50值低28和54倍,比市售片剂的IC50值低13和21倍。此外,与未经加工的片剂(27%),市售的片剂(45%)相比,相同剂量(2 mg / kg)的ARTM纳米晶体对间日疟原虫的寄生虫百分率(89%)降低显着(P <0.05)。和微悬架(60%)。急性毒性研究表明,口服ARTM纳米晶体的LD50值在1,500 mg / kg至2,000 mg / kg之间。这项研究表明,湿磨技术(Dena ® DM-100)可以生产ARTM的智能纳米晶体,具有增强的抗疟活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号